Literature DB >> 19958802

Enhancement of protein transduction-mediated nuclear delivery by interaction with dynein/microtubules.

Gregory W Moseley1, Denisse L Leyton, Dominic J Glover, Richard P Filmer, David A Jans.   

Abstract

Nucleocytoplasmic trafficking is a major consideration for the design of vehicles for the delivery of drug/DNA cargo to cell nuclei for cancer and gene therapies. Recent data indicate that efficient nuclear import can involve the microtubule (MT)/dynein network, such that nuclear delivery of exogenous cargo could be enhanced by attachment to peptide modules mediating association with dynein components, but this has not been investigated. Here, we report that the nuclear delivery of an exogenous cargo that enters the cell by protein transduction can be enhanced by attachment to a dynein-association sequence, with dependence on the MT network. This indicates that dynein/MT-association modules may provide useful modules for DNA/drug delivery approaches. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19958802     DOI: 10.1016/j.jbiotec.2009.11.015

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  3 in total

1.  Conservation of a unique mechanism of immune evasion across the Lyssavirus genus.

Authors:  L Wiltzer; F Larrous; S Oksayan; N Ito; G A Marsh; L F Wang; D Blondel; H Bourhy; D A Jans; G W Moseley
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

Review 2.  The pharmacology of regenerative medicine.

Authors:  George J Christ; Justin M Saul; Mark E Furth; Karl-Erik Andersson
Journal:  Pharmacol Rev       Date:  2013-07-01       Impact factor: 25.468

3.  A novel nuclear trafficking module regulates the nucleocytoplasmic localization of the rabies virus interferon antagonist, P protein.

Authors:  Sibil Oksayan; Linda Wiltzer; Caitlin L Rowe; Danielle Blondel; David A Jans; Gregory W Moseley
Journal:  J Biol Chem       Date:  2012-06-14       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.